2 EYES VISION SL

Their core work

2 EYES VISION SL is a Madrid-based medtech SME developing ophthalmic technology for vision correction and eye diagnostics. Their flagship work centers on SimVis — a simulation platform that lets eye care professionals demonstrate to patients how multifocal or presbyopia-correcting lenses will perform before committing to a prescription. Beyond simulation, they participate in research on personalized eye diagnostics that combine optical coherence tomography (OCT) with corneal biomechanics to enable patient-specific treatment planning. Their dual positioning — technology developer and clinical research partner — makes them a compact but technically specific player in European ophthalmic innovation.

What they specialise in

How they've shifted over time

In their first H2020 engagement (2017–2018), 2EYES focused on validating their own proprietary technology — SimVis — through an SME instrument project, reflecting a startup-phase commercialisation push with no published clinical keywords. By 2018–2022, their participation in IMCUSTOMEYE marks a clear shift toward deep clinical science: OCT, corneal biomechanics, and eye disease diagnostics entered their profile, suggesting they moved from product validation into broader research-backed clinical partnerships. The trajectory points from tool-maker to embedded clinical technology provider.

2EYES is moving deeper into clinical diagnostics, combining their optical device expertise with imaging science — making them a natural partner for ophthalmic AI, retinal imaging, or precision medicine projects.

How they like to work

2EYES has demonstrated both roles — project coordinator on SimVisTec and consortium participant on IMCUSTOMEYE — which is unusual for a two-project SME and suggests active strategic flexibility. Their 10 unique partners across just 2 projects indicates they engage in mid-sized consortia rather than large industrial partnerships. There is no evidence of repeat partners, so they appear to seek complementary expertise rather than stable long-term consortia.

2EYES has worked with 10 unique partners spanning 6 countries across only 2 projects, suggesting they punch above their size in network breadth. Their European reach reflects the cross-border clinical and technical collaborations typical of ophthalmology research consortia.

What sets them apart

2EYES occupies a rare niche as an SME that simultaneously develops its own commercial ophthalmic simulation product and participates in fundamental clinical research — giving them credibility with both industry and academia. Most vision technology companies in Spain focus on manufacturing optics or distributing medical devices; 2EYES is building proprietary IP at the intersection of simulation software and diagnostic imaging. For consortium builders, they bring a commercially motivated perspective to ophthalmic research, which can help translate results toward clinical adoption faster.

Highlights from their portfolio

• IMCUSTOMEYE
  The largest-funded project (EUR 186,168) and most technically rich, combining OCT imaging, corneal biomechanics, and ophthalmology under a personalised diagnostics framework — demonstrating 2EYES' ability to contribute alongside larger clinical research partners.
• SimVisTec
  Coordinated by 2EYES as the lead organisation, this project validates their proprietary SimVis technology — the core commercial asset of the company — through an EU-funded instrument specifically designed for SME market validation.